Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
4,973
archived clinical trials in
High Cholesterol

Genotype-Phenotype Associations in Pediatric Cardiomyopathy (PCM GENES)
Genotype-Phenotype Associations in Pediatric Cardiomyopathy
Status: Enrolling
Updated:  4/30/2018
Monroe Carell Jr. Children's Hospital at Vanderbilt
mi
from
Nashville, TN
Genotype-Phenotype Associations in Pediatric Cardiomyopathy (PCM GENES)
Genotype-Phenotype Associations in Pediatric Cardiomyopathy
Status: Enrolling
Updated: 4/30/2018
Monroe Carell Jr. Children's Hospital at Vanderbilt
mi
from
Nashville, TN
Click here to add this to my saved trials
Genotype-Phenotype Associations in Pediatric Cardiomyopathy (PCM GENES)
Genotype-Phenotype Associations in Pediatric Cardiomyopathy
Status: Enrolling
Updated:  4/30/2018
Primary Children's Medical Center
mi
from
Salt Lake City, UT
Genotype-Phenotype Associations in Pediatric Cardiomyopathy (PCM GENES)
Genotype-Phenotype Associations in Pediatric Cardiomyopathy
Status: Enrolling
Updated: 4/30/2018
Primary Children's Medical Center
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Genotype-Phenotype Associations in Pediatric Cardiomyopathy (PCM GENES)
Genotype-Phenotype Associations in Pediatric Cardiomyopathy
Status: Enrolling
Updated:  4/30/2018
Stollery Children's Hospital
mi
from
Edmonton,
Genotype-Phenotype Associations in Pediatric Cardiomyopathy (PCM GENES)
Genotype-Phenotype Associations in Pediatric Cardiomyopathy
Status: Enrolling
Updated: 4/30/2018
Stollery Children's Hospital
mi
from
Edmonton,
Click here to add this to my saved trials
Genotype-Phenotype Associations in Pediatric Cardiomyopathy (PCM GENES)
Genotype-Phenotype Associations in Pediatric Cardiomyopathy
Status: Enrolling
Updated:  4/30/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Genotype-Phenotype Associations in Pediatric Cardiomyopathy (PCM GENES)
Genotype-Phenotype Associations in Pediatric Cardiomyopathy
Status: Enrolling
Updated: 4/30/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Cardiac Biomarkers in Pediatric Cardiomyopathy (PCM Biomarkers)
Cardiac Biomarkers in Pediatric Cardiomyopathy
Status: Enrolling
Updated:  4/30/2018
Children's Hospital Colorado
mi
from
Aurora, CO
Cardiac Biomarkers in Pediatric Cardiomyopathy (PCM Biomarkers)
Cardiac Biomarkers in Pediatric Cardiomyopathy
Status: Enrolling
Updated: 4/30/2018
Children's Hospital Colorado
mi
from
Aurora, CO
Click here to add this to my saved trials
Cardiac Biomarkers in Pediatric Cardiomyopathy (PCM Biomarkers)
Cardiac Biomarkers in Pediatric Cardiomyopathy
Status: Enrolling
Updated:  4/30/2018
Ann and Robert H. Lurie Children's Hospital
mi
from
Chicago, IL
Cardiac Biomarkers in Pediatric Cardiomyopathy (PCM Biomarkers)
Cardiac Biomarkers in Pediatric Cardiomyopathy
Status: Enrolling
Updated: 4/30/2018
Ann and Robert H. Lurie Children's Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
Cardiac Biomarkers in Pediatric Cardiomyopathy (PCM Biomarkers)
Cardiac Biomarkers in Pediatric Cardiomyopathy
Status: Enrolling
Updated:  4/30/2018
Children's Hospital Boston
mi
from
Boston, MA
Cardiac Biomarkers in Pediatric Cardiomyopathy (PCM Biomarkers)
Cardiac Biomarkers in Pediatric Cardiomyopathy
Status: Enrolling
Updated: 4/30/2018
Children's Hospital Boston
mi
from
Boston, MA
Click here to add this to my saved trials
Cardiac Biomarkers in Pediatric Cardiomyopathy (PCM Biomarkers)
Cardiac Biomarkers in Pediatric Cardiomyopathy
Status: Enrolling
Updated:  4/30/2018
Children's Hospital at Montefiore
mi
from
Bronx, NY
Cardiac Biomarkers in Pediatric Cardiomyopathy (PCM Biomarkers)
Cardiac Biomarkers in Pediatric Cardiomyopathy
Status: Enrolling
Updated: 4/30/2018
Children's Hospital at Montefiore
mi
from
Bronx, NY
Click here to add this to my saved trials
Cardiac Biomarkers in Pediatric Cardiomyopathy (PCM Biomarkers)
Cardiac Biomarkers in Pediatric Cardiomyopathy
Status: Enrolling
Updated:  4/30/2018
Children's Hospital of New York, Columbia Presbyterian Medical Center
mi
from
New York, NY
Cardiac Biomarkers in Pediatric Cardiomyopathy (PCM Biomarkers)
Cardiac Biomarkers in Pediatric Cardiomyopathy
Status: Enrolling
Updated: 4/30/2018
Children's Hospital of New York, Columbia Presbyterian Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Cardiac Biomarkers in Pediatric Cardiomyopathy (PCM Biomarkers)
Cardiac Biomarkers in Pediatric Cardiomyopathy
Status: Enrolling
Updated:  4/30/2018
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Cardiac Biomarkers in Pediatric Cardiomyopathy (PCM Biomarkers)
Cardiac Biomarkers in Pediatric Cardiomyopathy
Status: Enrolling
Updated: 4/30/2018
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Cardiac Biomarkers in Pediatric Cardiomyopathy (PCM Biomarkers)
Cardiac Biomarkers in Pediatric Cardiomyopathy
Status: Enrolling
Updated:  4/30/2018
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Cardiac Biomarkers in Pediatric Cardiomyopathy (PCM Biomarkers)
Cardiac Biomarkers in Pediatric Cardiomyopathy
Status: Enrolling
Updated: 4/30/2018
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Cardiac Biomarkers in Pediatric Cardiomyopathy (PCM Biomarkers)
Cardiac Biomarkers in Pediatric Cardiomyopathy
Status: Enrolling
Updated:  4/30/2018
Children's Hospital of Pittsburgh of UMPC
mi
from
Pittsburgh, PA
Cardiac Biomarkers in Pediatric Cardiomyopathy (PCM Biomarkers)
Cardiac Biomarkers in Pediatric Cardiomyopathy
Status: Enrolling
Updated: 4/30/2018
Children's Hospital of Pittsburgh of UMPC
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Cardiac Biomarkers in Pediatric Cardiomyopathy (PCM Biomarkers)
Cardiac Biomarkers in Pediatric Cardiomyopathy
Status: Enrolling
Updated:  4/30/2018
Le Bonheur Children's Hospital
mi
from
Memphis, TN
Cardiac Biomarkers in Pediatric Cardiomyopathy (PCM Biomarkers)
Cardiac Biomarkers in Pediatric Cardiomyopathy
Status: Enrolling
Updated: 4/30/2018
Le Bonheur Children's Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Cardiac Biomarkers in Pediatric Cardiomyopathy (PCM Biomarkers)
Cardiac Biomarkers in Pediatric Cardiomyopathy
Status: Enrolling
Updated:  4/30/2018
Monroe Carell Jr. Children's Hospital at Vanderbilt
mi
from
Nashville, TN
Cardiac Biomarkers in Pediatric Cardiomyopathy (PCM Biomarkers)
Cardiac Biomarkers in Pediatric Cardiomyopathy
Status: Enrolling
Updated: 4/30/2018
Monroe Carell Jr. Children's Hospital at Vanderbilt
mi
from
Nashville, TN
Click here to add this to my saved trials
Cardiac Biomarkers in Pediatric Cardiomyopathy (PCM Biomarkers)
Cardiac Biomarkers in Pediatric Cardiomyopathy
Status: Enrolling
Updated:  4/30/2018
Primary Children's Medical Center
mi
from
Salt Lake City, UT
Cardiac Biomarkers in Pediatric Cardiomyopathy (PCM Biomarkers)
Cardiac Biomarkers in Pediatric Cardiomyopathy
Status: Enrolling
Updated: 4/30/2018
Primary Children's Medical Center
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Cardiac Biomarkers in Pediatric Cardiomyopathy (PCM Biomarkers)
Cardiac Biomarkers in Pediatric Cardiomyopathy
Status: Enrolling
Updated:  4/30/2018
Stollery Children's Hospital, University of Alberta
mi
from
Edmonton,
Cardiac Biomarkers in Pediatric Cardiomyopathy (PCM Biomarkers)
Cardiac Biomarkers in Pediatric Cardiomyopathy
Status: Enrolling
Updated: 4/30/2018
Stollery Children's Hospital, University of Alberta
mi
from
Edmonton,
Click here to add this to my saved trials
Cardiac Biomarkers in Pediatric Cardiomyopathy (PCM Biomarkers)
Cardiac Biomarkers in Pediatric Cardiomyopathy
Status: Enrolling
Updated:  4/30/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Cardiac Biomarkers in Pediatric Cardiomyopathy (PCM Biomarkers)
Cardiac Biomarkers in Pediatric Cardiomyopathy
Status: Enrolling
Updated: 4/30/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated:  4/30/2018
Clinical Research Facility
mi
from
Idaho Falls, ID
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated: 4/30/2018
Clinical Research Facility
mi
from
Idaho Falls, ID
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated:  4/30/2018
Clinical Research Facility
mi
from
Las Vegas, NV
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated: 4/30/2018
Clinical Research Facility
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated:  4/30/2018
Clinical Research Facility
mi
from
Bend, OR
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated: 4/30/2018
Clinical Research Facility
mi
from
Bend, OR
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated:  4/30/2018
Clinical Research Facility
mi
from
Northridge, CA
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated: 4/30/2018
Clinical Research Facility
mi
from
Northridge, CA
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated:  4/30/2018
Clinical Research Facility
mi
from
Louisville, KY
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated: 4/30/2018
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated:  4/30/2018
Clinical Research Facility
mi
from
Fargo, ND
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated: 4/30/2018
Clinical Research Facility
mi
from
Fargo, ND
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated:  4/30/2018
Clinical Research Facility
mi
from
Marion, OH
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated: 4/30/2018
Clinical Research Facility
mi
from
Marion, OH
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated:  4/30/2018
Clinical Research Facility
mi
from
Dallas, TX
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated: 4/30/2018
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated:  4/30/2018
Clinical Research Facility
mi
from
Salt Lake City, UT
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated: 4/30/2018
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated:  4/30/2018
Research Site
mi
from
Herston,
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated: 4/30/2018
Research Site
mi
from
Herston,
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated:  4/30/2018
Clinical Research Facility
mi
from
Little Rock, AR
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated: 4/30/2018
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated:  4/30/2018
Clinical Research Facility
mi
from
Fresno, CA
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated: 4/30/2018
Clinical Research Facility
mi
from
Fresno, CA
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated:  4/30/2018
Clinical Research Facility
mi
from
Huntington Beach, CA
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated: 4/30/2018
Clinical Research Facility
mi
from
Huntington Beach, CA
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated:  4/30/2018
Clinical Research Facility
mi
from
La Jolla, CA
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated: 4/30/2018
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated:  4/30/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated: 4/30/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated:  4/30/2018
Clinical Research Facility
mi
from
Port Hueneme, CA
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated: 4/30/2018
Clinical Research Facility
mi
from
Port Hueneme, CA
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated:  4/30/2018
Clinical Research Facility
mi
from
Tarzana, CA
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated: 4/30/2018
Clinical Research Facility
mi
from
Tarzana, CA
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated:  4/30/2018
Clinical Research Facility
mi
from
Tustin, CA
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated: 4/30/2018
Clinical Research Facility
mi
from
Tustin, CA
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated:  4/30/2018
Clinical Research Facility
mi
from
Chicago, IL
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated: 4/30/2018
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated:  4/30/2018
Clinical Research Facility
mi
from
Springfield, IL
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated: 4/30/2018
Clinical Research Facility
mi
from
Springfield, IL
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated:  4/30/2018
Clinical Research Facility
mi
from
Morehead City, NC
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated: 4/30/2018
Clinical Research Facility
mi
from
Morehead City, NC
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated:  4/30/2018
Clinical Research Facility
mi
from
Columbus, OH
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated: 4/30/2018
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated:  4/30/2018
Clinical Research Facility
mi
from
Chattanooga, TN
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated: 4/30/2018
Clinical Research Facility
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated:  4/30/2018
Clinical Research Facility
mi
from
Knoxville, TN
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated: 4/30/2018
Clinical Research Facility
mi
from
Knoxville, TN
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated:  4/30/2018
Clinical Research Facility
mi
from
Houston, TX
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated: 4/30/2018
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated:  4/30/2018
Clinical Research Facility
mi
from
Round Rock, TX
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated: 4/30/2018
Clinical Research Facility
mi
from
Round Rock, TX
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated:  4/30/2018
Clinical Research Facility
mi
from
Tomball, TX
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated: 4/30/2018
Clinical Research Facility
mi
from
Tomball, TX
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated:  4/30/2018
Clinical Research Facility
mi
from
Chesapeake, VA
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated: 4/30/2018
Clinical Research Facility
mi
from
Chesapeake, VA
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated:  4/30/2018
Clinical Research Facility
mi
from
Bradenton, FL
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated: 4/30/2018
Clinical Research Facility
mi
from
Bradenton, FL
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated:  4/30/2018
Clinical Research Facility
mi
from
Ocoee, FL
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated: 4/30/2018
Clinical Research Facility
mi
from
Ocoee, FL
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated:  4/30/2018
Clinical Research Facility
mi
from
Tampa, FL
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated: 4/30/2018
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated:  4/30/2018
Clinical Research Facility
mi
from
Stockbridge, GA
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated: 4/30/2018
Clinical Research Facility
mi
from
Stockbridge, GA
Click here to add this to my saved trials
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated:  4/30/2018
Clinical Research Facility
mi
from
Evanston, IL
Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)
A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Risk With Non-HDL-C Not Adequately Controlled With Maximally Tolerated Statin Therapy
Status: Enrolling
Updated: 4/30/2018
Clinical Research Facility
mi
from
Evanston, IL
Click here to add this to my saved trials